Boosting the anticancer activity of doxorubicin with a layered double hydroxide nanocarrier
Source abstract
Abstract
Abstract A cationic anticancer drug, doxorubicin (DOX), was intercalated into layered double hydroxide (LDH) with an anionic polymer (polyacrylic acid (PAA)) to introduce the advantages of LDH as a drug carrier to DOX. Through X-ray diffraction patterns, Fourier-transform-infrared spectra, zeta-potential and X-ray photoelectron spectra showed that, PAA and DOX were intercalated in LDH interlayers through electrostatic stabilization between the carboxylate of PAA and LDH layer and between the carboxylate PAA backbone and DOX. Scanning electron microscopic images and dynamic light scattering results revealed that the DOX-PAA-LDH hybrid showed a favorable size for cellular uptake and enhanced permeability and retention, with a ~ 300 nm hydrodynamic radius and ~ 160 nm primary particle size. According to the bio-transmission electron microscopic images and confocal microscopic images, the DOX-PAA-LDH hybrid continuously provides drugs to endosomal cells during endocytosis and exocytosis. In accordance with these results, DOX-PAA-LDH showed improved anticancer activity against human osteosarcoma cells (MG-63) and human lung adenocarcinoma epithelial cells (A549) due to the advantages of LDH as a drug carrier.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Layered Double Hydroxides Synthesis and Applications · Magnesium Oxide Properties and Applications · Mesoporous Materials and Catalysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (60)
Show source-provided references
1. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells10.1016/j.jconrel.2008.09.008 ↗
2. A reexamination of hydrotalcite crystal chemistry10.1021/jp960039j ↗
3. The opposite effects of doxorubicin on bone marrow stem cells versus breast cancer stem cells depend on glucosylceramide synthase10.1016/j.biocel.2012.06.010 ↗
4. Cellular uptake and internalization of hyaluronan-based doxorubicin and cisplatin conjugates10.3109/1061186X.2014.921924 ↗
5. pH-sensitive ZnO quantum dots–doxorubicin nanoparticles for lung cancer targeted drug delivery10.1021/acsami.6b04933 ↗
6. Hydrotalcite-type anionic clays: Preparation, properties and applications10.1016/0920-5861(91)80068-K ↗
7. Doxorubicin cardiomyopathy10.1159/000265166 ↗
8. Cellular toxicity of inorganic hydroxide nanoparticles10.1166/jnn.2007.18081 ↗
9. Safety aspect of inorganic layered nanoparticles: size-dependency in vitro and in vivo10.1166/jnn.2008.1143 ↗
10. Anticancer drug encapsulated in inorganic lattice can overcome drug resistance10.1039/b925831k ↗
11. Layered double hydroxide as an efficient drugreservoir for folate derivatives10.1016/j.biomaterials.2003.09.083 ↗
12. Intracellular trafficking pathway of layered double hydroxide nanoparticles in human cells: Size-dependent cellular delivery10.1016/j.clay.2012.06.007 ↗
13. Aggregation of montmorillonite and organic matter in aqueous media containing artificial seawater10.1186/1467-4866-10-2 ↗
14. Combinatory Treatment with miR-7-5p and Drug-Loaded Cubosomes Effectively Impairs Cancer Cells10.3390/ijms21145039 ↗
15. Iron N-(2-hydroxy acetophenone) glycinate (FeNG), a non-toxic glutathione depletor circumvents doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo10.1007/s10534-011-9493-7 ↗
16. Treatment of carcinoma in situ of the bladder with doxorubicin (Adriamycin)10.1007/BF00256715 ↗
17. Cancer of the breast10.1056/NEJM198001103020203 ↗
18. Incorporation of Glycine max Merrill Extract into Layered double Hydroxide through Ion-Exchange and reconstruction10.3390/nano9091262 ↗
19. Intracrystalline structure and release pattern of ferulic acid intercalated into layered double hydroxide through various synthesis routes10.1016/j.clay.2015.04.015 ↗
20. Ultrasmall platinum nanoparticles enable deep tumor penetration and synergistic therapeutic abilities through free radical species-assisted catalysis to combat cancer multidrug resistance10.1016/j.cej.2019.123138 ↗
21. Chitosan overlaid Fe3O4/rGO nanocomposite for targeted drug delivery, imaging, and biomedical applications10.1038/s41598-020-76015-3 ↗
22. Doxorubicin loaded PVA coated iron oxide nanoparticles for targeted drug delivery10.1016/j.msec.2010.01.006 ↗
23. Nano-biohybrids of engineered nanoclays and natural extract for antibacterial agents10.1016/j.clay.2016.05.003 ↗
24. Layered double hydroxide nanomaterials encapsulating Angelica gigas Nakai extract for potential anticancer nanomedicine10.3389/fphar.2018.00723 ↗
25. PEG-PE/clay composite carriers for doxorubicin: effect of composite structure on release, cell interction and cytotoxicity10.1016/j.actbio.2017.04.008 ↗
26. Layered double hydoxide nanoparticles for biomedical applications: current status and recent prospects10.1016/j.clay.2015.04.018 ↗
27. Ion-Exchange reactions and photothermal patterning of monolayer assembled polyacrylate-layered double hydroxide nanocomposites on solid substrates10.1021/cm060278b ↗
28. The impact of cation acidity and alkyl substituents on the cation–anion interactions of 1-alkyl-2,3-dimethylimidazolium ionic liquids10.1039/C9CP01381D ↗
29. Engineered pH-responsive Hydrazone-carboxylate complexes-encapsulated 2D matrices for Cathepsin-mediated apoptosis in cancer10.1002/jbm.a.36610 ↗
30. Subcellular performance of nanoparticles in cancer therapy10.2147/IJN.S226186 ↗
31. Layered double hydroxide assemblies with controllable drug loading capacity and release behavior as well as stabilized layer-by-layer polymer multilayers10.1021/acsami.5b04569 ↗
32. Successful transfer of plasmid DNA into in vitro cells transfected with an inorganic plasmid–Mg/Al-LDH nanobiocomposite material as a vector for gene expression
33. Design and evaluation of clickable gelatin-oleic nanoparticles using fattigation-platform for cancer therapy10.1016/j.ijpharm.2018.04.047 ↗
34. Cellular Uptake Mechanism of an Inorganic Nanovehicle and its Drug Conjugates: Enhanced Efficacy due to Clathrin-Mediated Endocytosis10.1021/bc0601323 ↗
35. Intracrystalline structure of DNA molecules stabilized in the layered double hydroxide10.1016/j.jpcs.2006.01.080 ↗
36. Efficient delivery of anticancer drug MTX through MTX-LDH nanohybrid system10.1016/j.jpcs.2006.01.033 ↗
37. Inorganic drug-delivery nanovehicle conjugated with cancer-cell-specific ligand10.1002/adfm.200801127 ↗
38. Inorganic metal hydroxide nanoparticles for targeted cellular uptake through clathrin-mediated endocytosis10.1002/asia.200800290 ↗
39. Intracellular drug delivery of layered double hydroxide nanoparticles10.1166/jnn.2011.3409 ↗
40. Biodegradable inorganic nanovector: Passive versus active tumor targeting in siRNA transportation10.1002/anie.201510844 ↗
41. Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia10.1097/00007691-198903000-00004 ↗
42. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs10.1016/j.chembiol.2010.04.012 ↗
43. Synthesis of photoluminescent glycodendrimer with terminal β-cyclodextrin molecules as a biocompatible pH-sensitive carrier for doxorubicin delivery10.1016/j.carbpol.2020.116658 ↗
44. The in vitro sustained release profile and antitumor effect of etoposide-layered double hydroxide nanohybrids10.2147/IJN.S43203 ↗
45. Rives · 2001
46. Chelator-Free labeling of layered double hydroxide nanoparticles for in vivo PET imaging10.1038/srep16930 ↗
47. Water-soluble galactosamine derivative of β-cyclodextrin as protective ligand and targeted carrier for delivery of toxic anthracycline drug10.1016/j.ijpharm.2020.119834 ↗
48. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems10.1111/j.2042-7158.2012.01567.x ↗
49. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial10.1016/S0140-6736(16)30587-6 ↗
50. Tailoring hybrid layered double hydroxides for the development of innovative applications10.1002/adfm.201703868 ↗
51. Development of a graphene oxide nanocarrier for dual-drug chemo-phototherapy to overcome drug resistance in cancer10.1021/acsami.5b10426 ↗
52. Polydopamine and peptide decorated doxorubicin-loaded mesoporous silica nanoparticles as a targeted drug delivery system for bladder cancer therapy10.1080/10717544.2017.1309475 ↗
53. A nanodrug consisting of Doxorubicin and exosome derived from mesenchymal stem cells for osteosarcoma treatment in vitro10.2147/IJN.S218988 ↗
54. Combined effects of graphene oxide and zinc oxide nanoparticle on human A549 cells: Bioavailability, toxicity and mechanisms10.1039/C8EN00965A ↗
55. Doxoubicin intercalated copper diethyldithiocarbamate functionalized layered double hydroxide hybrid nanoparticles for targeted therapy of hepatocellular carcinoma10.1039/C9BM01394F ↗
56. Doxorubicin-loaded glycyrrhetinic acid-modified alginate nanoparticles for liver tumor chemotherapy10.1016/j.biomaterials.2011.11.045 ↗
57. Doxorubicin-conjugated PAMAM dendrimers for pH-responsive drug release and folic acid-targeted cancer therapy10.3390/pharmaceutics10030162 ↗
58. Enhanced anticancer performances of doxorubicin loaded macro-mesoporous silica nanoparticles with host-metal-guest structure10.1016/j.micromeso.2020.110589 ↗
59. Advances in delivery systems for doxorubicin10.4172/2157-7439.1000519 ↗
60. Encapsulation of doxorubicin within multifunctional gadolinium-loaded dendrimer nanocomplexes for targeted theranostics of cancer cells10.1039/C5RA01215E ↗